Abstract
Purpose: Primary chemotherapy provides an ideal opportunity to correlate potential non-invasive surrogate markers of angiogenesis with tumor microvessel density (MVD) and response. Patients and methods: Patients with newly diagnosed stages II or III breast cancer were treated with sequential doxorubicin 75 mg/M2 q2 wks × 3 and docetaxel 40 mg/M2 weekly × 6; treatment order was randomly assigned. Potential serologic and imaging markers of angiogenesis were obtained pre-treatment, at crossover and completion of chemotherapy. Non-invasive biomarkers were correlated with MVD and pathologic response. Results: From June 1999 to October 2002, 70 patients were entered. Median pretreatment tumor diameter was 6.0 cm with clinically involved axillary nodes in 33 (47%) patients; 20% had inflammatory disease. Clinical response rate was 91%, including 46% clinical complete responses. Pathologic complete response (pCR) was confirmed in 9 (12.8%) patients. Baseline MVD did not correlate with clinical or pathologic response. Serologic markers were obtained in all patients; basic fibroblast growth factor (bFGF) was lower at baseline and increased during treatment in patients with a pCR but did not correlate with MVD. Color Doppler ultrasound (CDUS) was completed in 47 patients; no parameter reliably correlated with MVD or response. Positron emission tomography (PET) with [F-18]-fluoro-deoxyglucose, [O-15]-water and [C-11]-carbon monoxide were completed in 19 patients; uptake of all tracers decreased during treatment in virtually all patients. Conclusion: Sequential doxorubicin and docetaxel is generally well tolerated and highly active. Serum angiogenic factors and imaging parameters frequently varied throughout treatment but did not correlate with MVD or consistently predict response.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
J Folkman (1990) ArticleTitleWhat is the evidence that tumors are angiogenesis dependent J Natl Cancer Inst 82 4–6 Occurrence Handle10.1093/jnci/82.1.4 Occurrence Handle1:STN:280:DyaK3c%2FnvF2qug%3D%3D Occurrence Handle1688381
Gasparini G: Angiogenesis in breast cancer. Role in biology, tumor progression, and prognosis. In: Bowcock A, NJ Totowa, (eds) Breast Cancer: Molecular Genetics, Pathogenesis, and Therapeutics, Humana Press Inc., 1999, pp 347–371.
K Miller C Sweeney G Sledge (2001) ArticleTitleRedefining the target: chemotherapeutics as antiangiogenics J Clin Oncol 19 1195–1206 Occurrence Handle1:CAS:528:DC%2BD3MXhvFertrY%3D Occurrence Handle11181686
N Klauber S Parangi E Flynn E Hamel R.J D’Amato (1997) ArticleTitleInhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and Taxol Cancer Res 57 81–86 Occurrence Handle8988045 Occurrence Handle1:CAS:528:DyaK2sXjvFOmtw%3D%3D
D Belotti V Vergani T Drudis P Borsotti MR Pitelli G Viale R Giavazzi G Taraboletti (1996) ArticleTitleThe microtubule-affecting drug paclitaxel has antiangiogenic activity Clin Cancer Res 2 1843–1849 Occurrence Handle9816139 Occurrence Handle1:CAS:528:DyaK28Xnt1SitLo%3D
CJ Sweeney KD Miller SE Sissons S Nozaki DK Heilman J Shen GW Sledge SuffixJr (2001) ArticleTitleThe antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors Cancer Res 61 3369–3372 Occurrence Handle11309294 Occurrence Handle1:CAS:528:DC%2BD3MXjtFSjur4%3D
U Benbow R Maitra J Hamilton C Brinckerhoff (1999) ArticleTitleSelective modulation of collagenase 1 gene expression by the chemotherapeutic agent doxorubicin Clin Cancer Res 5 203–208 Occurrence Handle9918220 Occurrence Handle1:CAS:528:DyaK1MXhtVShtbY%3D
E Lorenzo C Ruiz-Ruiz AJ Quesada G Hernandez A Rodriguez A Lopez-Rivas JM Redondo (2002) ArticleTitleDoxorubicin induces apoptosis and CD95 gene expression in human primary endothelial cells through a p53-dependent mechanism J Biol Chem 277 10883–10892 Occurrence Handle11779855 Occurrence Handle1:CAS:528:DC%2BD38Xis1KhtLk%3D
A Makris T Powles S Ashley J Chang T Hickish V Tidy A Nash H Ford (1998) ArticleTitleA reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer Ann Oncol 9 1179–1184 Occurrence Handle10.1023/A:1008400706949 Occurrence Handle1:STN:280:DyaK1M%2FnvFSnsg%3D%3D Occurrence Handle9862047
L Mauriac M Durand A Avril J-M Dilhuydy (1991) ArticleTitleEffects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm Ann Oncol 2 347–354 Occurrence Handle1:STN:280:DyaK38%2Fmt1KhsA%3D%3D Occurrence Handle1954179
S Scholl A Fourquet B Asselain J Pierga J Vilcoq J Durand T Dorval T Palangie M Jouve P Beuzeboc E Garcio-Giralt R Slamon A Rochefordiere Particlede la F Campana P Pouillart (1994) ArticleTitleNeoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumors considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. Eur J Cancer 30A 645–652 Occurrence Handle8080680 Occurrence Handle1:STN:280:DyaK2czmtFyltw%3D%3D
B Fisher J Bryant N Wolmark E Mamounas A Brown E Fisher D Wickerham M Begovic A DeCillis A Rabidoux R Margolese A Cruz J Hoehn A Lees D NV H Bear (1998) ArticleTitleEffect of preoperative chemotherapy on the outcome of women with operable breast cancer J Clin Oncol 16 2672–2685 Occurrence Handle1:CAS:528:DyaK1cXlsFCgurg%3D Occurrence Handle9704717
S Scholl J Pierga B Asselain P Beuzeboc T Dorval E Garcia-Giralt M Jouve T Palangie Y Remvikos J Durand A Fourquet P Pouillart (1995) ArticleTitleBreast tumor response to primary chemothrapy predicts local and distant control as well as survival. Eur J Cancer 31A 1969–1975 Occurrence Handle8562150 Occurrence Handle1:CAS:528:DyaK28XhtVOnurw%3D
K Laing J Ragaz N Le M Manji D McLarden S Yu S Jackson I Olivotto K Gelmon (1998) ArticleTitleCorrelation of modified radical mastectomy with outcome of stage III breast cancer patients treated with preoperative therapy: is there a need for randomized trials? Analysis of the British Columbia Study. Proc Am Soc Clin Oncol 17: 168a
P Valagussa M Zambetti G Bonadonna R Zucali G Mezzanotte U Veronesi (1990) ArticleTitlePrognostic factors in locally advanced noninflammatory breast cancer: Long term results following primary chemotherapy Breast Cancer Res Treat 15 137–147 Occurrence Handle2372569 Occurrence Handle1:STN:280:DyaK3czitF2ltw%3D%3D
O Tynninen J Sjostrom K vonBoguslawski NO Bengtsson R Heikkila P Malmstrom B Ostenstad E Wist V Valvere E Saksela T Paavonen C Blomqvist (2002) ArticleTitleTumour microvessel density as predictor of chemotherapy response in breast cancer patients Br J Cancer 86 1905–1908 Occurrence Handle12085184 Occurrence Handle1:CAS:528:DC%2BD38XkvVaiurc%3D
C Jennison B Turnbull (1983) ArticleTitleConfidence intervals for a binomial parameter following a multistage test with application to MIL-STD 105D and medical trials Technometrics 25 49–58
J Link C Forsthoff J Ibarra LW Rogers F Magy KA Maya (2003) ArticleTitleDose-dense doxorubicin, docetaxel and cyclophosphamide as sequential neoadjuvant therapy for high-risk breast cancer: a pilot study. Breast Cancer Res Treat 82(Suppl 1) S59
B Cooper P Silverman B Overmoyer R Shenk M Allen (2003) ArticleTitleStudy of dose-dense doxorubicin and docetaxel for patients with advanced operable and inoperable adenocarcinoma of the breast. Breast Cancer Res Treat 82 (Suppl 1) S57
KD Miller W McCaskill-Stevens J Sisk DM Loesch F Monaco R Seshadri GW Sledge SuffixJr (1999) ArticleTitleCombination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: A randomized pilot trial of the Hoosier Oncology Group J Clin Oncol 17 3033–3037 Occurrence Handle1:CAS:528:DyaK1MXmslGmt7k%3D Occurrence Handle10506597
B Esmaeli G Hortobagyi F Esteva V Valero MA Ahmadi D Booser N Ibrahim E Delpassand R Arbuckle (2002) ArticleTitleCanalicular stenosis secondary to weekly docetaxel: a potentially preventable side effect Ann Oncol 13 218–221 Occurrence Handle11885997 Occurrence Handle1:STN:280:DC%2BD387ltl2htQ%3D%3D
L Hidaji M Amir Ahmadi R Arbuckle V Valero E Rivera RA Newman S-M Tu P Mathew B Esmaeli (2003) ArticleTitleExcessive tearing and canalicular blockage as a side effect of docetaxel. Proc Am Soc Clin Oncol 22: 12
G Ganem M Tubiana-Hulin P Fumoleau M Combe JL Misset JM Vannetzel T Bachelot LR De Ybarlucea V Lotz B Bendahmane V Dieras (2003) ArticleTitlePhase II trial combining docetaxel and doxorubicin as neoadjuvant chemotherapy in patients with operable breast cancer Ann Oncol 14 1623–1628 Occurrence Handle10.1093/annonc/mdg449 Occurrence Handle1:STN:280:DC%2BD3srgtlWqsw%3D%3D Occurrence Handle14581269
G von Minckwitz SD Costa G Raab JU Blohmer H Eidtmann J Hilfrich E Merkle C Jackisch G Gademann AH Tulusan W Eiermann E Graf M Kaufmann (2001) ArticleTitleDose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomized, controlled, open phase IIb study J Clin Oncol 19 3506–3515 Occurrence Handle11481357 Occurrence Handle1:STN:280:DC%2BD3MvjtlOmtA%3D%3D
C Jackisch G Minckwitz Particlevon H Eidtmann SD Costa G Raab JU Blohmer M Schutte B Gerber E Merkle G Gademann D Lampe J Hilfrich AH Tulusan A Caputo M Kaufmann (2002) ArticleTitleDose-dense biweekly doxorubicin/docetaxel versus sequential neoadjuvant chemotherapy with doxorubicin/cyclophosphamide/docetaxel in operable breast cancer: second interim analysis Clin Breast Cancer 3 276–280 Occurrence Handle10.3816/CBC.2002.n.031 Occurrence Handle12425756 Occurrence Handle1:CAS:528:DC%2BD38XpsVygt78%3D
JA Zujewski J Eng-Wong J O’Shaughnessy D Venzon C Chow D Danforth DR Kohler G Cusack D Riseberg KH Cowan (2003) ArticleTitleA pilot study of dose intense doxorubicin and cyclophosphamide followed by infusional paclitaxel in high-risk primary breast cancer Breast Cancer Res Treat 81 41–51 Occurrence Handle14531496 Occurrence Handle1:CAS:528:DC%2BD3sXms1Gjsrg%3D
GW Sledge D Neuberg P Bernardo JN Ingle S Martino EK Rowinsky WC Wood (2003) ArticleTitlePhase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193) J Clin Oncol 21 588–592 Occurrence Handle12586793
B Linderholm B Lindh L Beckman B Tavelin K Grankvist J Bergh R Henriksson (2001) The prognostic value of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) and associations to first metastases site in 1307 patients with primary breast cancer. Proc Am Soc Clin Oncol 20:4a
JH Ellenberg (1994) ArticleTitleSelection bias in observational and experimental studies Stat Med 13 557–567 Occurrence Handle8023035 Occurrence Handle1:STN:280:DyaK2c3psVKltQ%3D%3D
S Yusuf J Wittes J Probstfield HA Tyroler (1991) ArticleTitleAnalysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials Jama 266 93–98 Occurrence Handle2046134 Occurrence Handle1:STN:280:DyaK3M3lvFKktg%3D%3D
V Stearns B Singh T Tsangaris JG Crawford A Novielli MJ Ellis C Isaacs M Pennanen C Tibery A Farhad R Slack DF Hayes (2003) ArticleTitleA prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer Clin Cancer Res 9 124–133 Occurrence Handle12538460 Occurrence Handle1:CAS:528:DC%2BD3sXnt1OmsQ%3D%3D
M Untch S Kahlert V Moebus C Thomssen B Muck F Von Bismarck D Wallwiener R Kreienberg (2003) ArticleTitleNegative steroid receptors are a good predictor for response to preoperative chemotherapy in breast cancer Proc Am Soc Clin Oncol 22 9
M Colleoni I Minchella G Mazzarol F Nole G Peruzzotti A Rocca G Viale L Orlando G Ferretti G Curigliano P Veronesi M Intra A Goldhirsch (2000) ArticleTitleResponse to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors Ann Oncol 11 1057–1059 Occurrence Handle11038046 Occurrence Handle1:STN:280:DC%2BD3cvoslOrug%3D%3D
A Makris TJ Powles M Dowsett CK Osborne PA Trott IN Fernando SE Ashley MG Ormerod JC Titley RK Gregory DC Allred (1997) ArticleTitlePrediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas Clin Cancer Res 3 593–600 Occurrence Handle9815725 Occurrence Handle1:STN:280:DyaK1M%2FjsFehtw%3D%3D
J Chang TJ Powles DC Allred SE Ashley GM Clark A Makris L Assersohn RK Gregory CK Osborne M Dowsett (1999) ArticleTitleBiologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer J Clin Oncol 17 3058–3063 Occurrence Handle10506600 Occurrence Handle1:STN:280:DyaK1MvjvVWksg%3D%3D
M Campiglio G Somenzi C Olgiati G Beretta A Balsari N Zaffaroni P Valagussa S Menard (2003) ArticleTitleRole of proliferation in HER2 status predicted response to doxorubicin Int J Cancer 105 568–573 Occurrence Handle12712452 Occurrence Handle1:CAS:528:DC%2BD3sXktlOqsbY%3D
M Colleoni E Orvieto F Nole L Orlando I Minchella G Viale G Peruzzotti C Robertson C Noberasco V Galimberti V Sacchini P Veronesi S Zurrida R Orecchia A Goldhirsch (1999) ArticleTitlePrediction of response to primary chemotherapy for operable breast cancer Eur J Cancer 35 574–579 Occurrence Handle10492630 Occurrence Handle1:STN:280:DyaK1Mvit1aqug%3D%3D
HJ Mackay D Cameron M Rahilly MJ Mackean J Paul SB Kaye R Brown (2000) ArticleTitleReduced MLH1 expression in breast tumors after primary chemotherapy predicts disease-free survival J Clin Oncol 18 87–93 Occurrence Handle10623697
P Regitnig A Reiner HP Dinges G Hofler E Muller-Holzner SF Lax P Obrist M Rudas F Quehenberger (2002) ArticleTitleQuality assurance for detection of estrogen and progesterone receptors by immunohistochemistry in Austrian pathology laboratories Virchows Arch 441 328–334 Occurrence Handle10.1007/s00428-002-0646-5 Occurrence Handle1:CAS:528:DC%2BD3sXkslSrsA%3D%3D Occurrence Handle12404057
HM Verkooijen JL Peterse ME Schipper E Buskens JH Hendriks RM Pijnappel PH Peeters IH Borel Rinkes WP Mali R Holland (2003) ArticleTitleInterobserver variability between general and expert pathologists during the histopathological assessment of large-core needle and open biopsies of non-palpable breast lesions Eur J Cancer 39 2187–2191 Occurrence Handle14522377 Occurrence Handle1:STN:280:DC%2BD3svmtVGlsA%3D%3D
TA Thomson MM Hayes JJ Spinelli E Hilland C Sawrenko D Phillips B Dupuis RL Parker (2001) ArticleTitleHER-2/neu in breast cancer: interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization Mod Pathol 14 1079–1086 Occurrence Handle11706067 Occurrence Handle1:STN:280:DC%2BD3MnltlarsA%3D%3D
RP Kedar DO Cosgrove IE Smith JL Mansi JC Bamber (1994) ArticleTitleBreast carcinoma: measurement of tumor response to primary medical therapy with color Doppler flow imaging Radiology 190 825–830 Occurrence Handle8115634 Occurrence Handle1:STN:280:DyaK2c7lvFyrsw%3D%3D
M Schelling N Avril J Nahrig W Kuhn W Romer D Sattler M Werner J Dose F Janicke H Graeff M Schwaiger (2000) ArticleTitlePositron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer J Clin Oncol 18 1689–1695 Occurrence Handle1:STN:280:DC%2BD3c3islyjsw%3D%3D Occurrence Handle10764429
RL Wahl K Zasadny M Helvie GD Hutchins B Weber R Cody (1993) ArticleTitleMetabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation J Clin Oncol 11 2101–2111 Occurrence Handle1:STN:280:DyaK2c%2FksFyisQ%3D%3D Occurrence Handle8229124
T Jansson JE Westlin H Ahlstrom A Lilja B Langstrom J Bergh (1995) ArticleTitlePositron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation J Clin Oncol 13 1470–1477 Occurrence Handle1:STN:280:DyaK2M3ntFaksA%3D%3D Occurrence Handle7751894
P Bassa EE Kim T Inoue FC Wong M Korkmaz DJ Yang WH Wong KW Hicks AU Buzdar DA Podoloff (1996) ArticleTitleEvaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer J Nucl Med 37 931–938 Occurrence Handle1:CAS:528:DyaK28Xkt1KlsL4%3D Occurrence Handle8683314
D Mankoff L Dunnwald J Gralow GK Ellis MJ Drucker RB Livingston (1999) ArticleTitleMonitoring the response of patients with locally advanced breast carcinoma to neoadjuvant chemotherapy using {technetium 99m}-sestamibi scintimammography Cancer 85 2410–2423 Occurrence Handle10357412 Occurrence Handle1:CAS:528:DyaK1MXjvFyjtLs%3D
IC Smith AE Welch AW Hutcheon ID Miller S Payne F Chilcott S Waikar T Whitaker AK Ah-See O Eremin SD Heys FJ Gilbert PF Sharp (2000) ArticleTitlePositron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy J Clin Oncol 18 1676–1688 Occurrence Handle1:STN:280:DC%2BD3c3islyjsg%3D%3D Occurrence Handle10764428
C Peters-Engl M Medl M Mirau C Wanner S Bilgi P Sevelda A Obermair (1998) ArticleTitleColor-coded and spectral Doppler flow in breast carcinomas–relationship with the tumor microvasculature Breast Cancer Res Treat 47 83–89 Occurrence Handle10.1023/A:1005992916193 Occurrence Handle9493979 Occurrence Handle1:STN:280:DyaK1c7lt12qug%3D%3D
WJ Lee JS Chu SJ Houng MF Chung SM Wang KM Chen (1995) ArticleTitleBreast cancer angiogenesis: a quantitative morphologic and Doppler imaging study Ann Surg Oncol 2 246–251 Occurrence Handle7543800 Occurrence Handle1:STN:280:DyaK2MzmvVCnsQ%3D%3D
R Bos JJ Hoeven Particlevan Der E Wall Particlevan Der P Groep Particlevan Der PJ Diest Particlevan EF Comans U Joshi GL Semenza OS Hoekstra AA Lammertsma CF Molthoff (2002) ArticleTitleBiologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography J Clin Oncol 20 379–387 Occurrence Handle10.1200/JCO.20.2.379 Occurrence Handle1:CAS:528:DC%2BD38XovVKisQ%3D%3D Occurrence Handle11786564
KR Zasadny M Tatsumi RL Wahl (2003) ArticleTitleFDG metabolism and uptake versus blood flow in women with untreated primary breast cancers Eur J Nucl Med Mol Imaging 30 274–280 Occurrence Handle1:CAS:528:DC%2BD3sXms1Cnuw%3D%3D Occurrence Handle12552346 Occurrence Handle10.1007/s00259-002-1022-z
DA Mankoff LK Dunnwald JR Gralow GK Ellis A Charlop TJ Lawton EK Schubert J Tseng RB Livingston (2002) ArticleTitleBlood flow and metabolism in locally advanced breast cancer: relationship to response to therapy J Nucl Med 43 500–509 Occurrence Handle11937594
DA Mankoff LK Dunnwald JR Gralow GK Ellis EK Schubert J Tseng TJ Lawton HM Linden RB Livingston (2003) ArticleTitleChanges in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy J Nucl Med 44 1806–1814 Occurrence Handle14602864
AG Douglas-Jones N Collett JM Morgan B Jasani (2001) ArticleTitleComparison of core oestrogen receptor (ER) assay with excised tumour: intratumoral distribution of ER in breast carcinoma J Clin Pathol 54 951–955 Occurrence Handle11729216 Occurrence Handle1:STN:280:DC%2BD3Mnot1yqsQ%3D%3D
TW Jacobs KP Siziopikou JE Prioleau S Raza JK Baum DF Hayes SJ Schnitt (1998) ArticleTitleDo prognostic marker studies on core needle biopsy specimens of breast carcinoma accurately reflect the marker status of the tumor Mod Pathol 11 259–264 Occurrence Handle9521472 Occurrence Handle1:STN:280:DyaK1c7otVOluw%3D%3D
JC Chang EC Wooten A Tsimelzon SG Hilsenbeck MC Gutierrez R Elledge S Mohsin CK Osborne GC Chamness DC Allred P O’Connell (2003) ArticleTitleGene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer Lancet 362 362–369 Occurrence Handle12907009 Occurrence Handle1:CAS:528:DC%2BD3sXlvFGnsLo%3D
Pusztai L, Ayers M, Simmans F, Damokosh A, Hess K, Valero V, Clark E, Ross J, Hortobagyi G, Stec J: Emerging science: Prospective validation of gene expression profiling-based prediction of complete pathologic response to neoadjuvant paclitaxel/FAC chemotherapy in breast cancer. Proc Am Soc Clin Oncol 22: Abstract 1, 2003
L Pusztai M Ayers J Stec E Clark K Hess D Stivers A Damokosh N Sneige TA Buchholz FJ Esteva B Arun M Cristofanilli D Booser M Rosales V Valero C Adams GN Hortobagyi WF Symmans (2003) ArticleTitleGene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors Clin Cancer Res 9 2406–2415 Occurrence Handle12855612 Occurrence Handle1:CAS:528:DC%2BD3sXlt1ykurw%3D
SE Soule S Shak J Baker M Cronin M-L Liu S Badve KD Miller GW Sledge (2003) ArticleTitlePredicting response to chemotherapy in invasive breast cancer: Gene expression profiling of paraffin-embedded core biopsy tissue Proc Am Soc Clin Oncol 22 862
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Miller, K.D., Soule, S.E., Calley, C. et al. Randomized phase II trial of the anti-angiogenic potential of doxorubicin and docetaxel; primary chemotherapy as Biomarker Discovery Laboratory. Breast Cancer Res Treat 89, 187–197 (2005). https://doi.org/10.1007/s10549-004-2044-y
Issue Date:
DOI: https://doi.org/10.1007/s10549-004-2044-y